Cost‐Effectiveness of Fracture Prevention in Postmenopausal Women With Early Breast Cancer in China
One-time BMD screening with selective alendronate for osteoporosis is cost-effective for Chinese women aged ≥ 60 receiving AIs, aligning with China's healthcare constraints. Universal therapy becomes favourable for older or high-risk subgroups. These data-driven findings support tailored strategies to optimise bone health management and resource allocation.
Authors
- Ruxu You (ORCID: https://orcid.org/0000-0003-3057-4462)
- Takahiro Mori (ORCID: https://orcid.org/0000-0001-7324-8574)
- Kensuke Moriwaki (ORCID: https://orcid.org/0000-0001-5800-597X)
- Jinyu Liu (ORCID: https://orcid.org/0000-0002-3101-2587)
- Ting Liu (ORCID: https://orcid.org/0000-0003-1816-5551)
- Yu Zhang
- Lin Wang (ORCID: https://orcid.org/0000-0003-2433-8594)
- Yihan Chen (ORCID: https://orcid.org/0000-0003-1000-1835)
- Xihan Lin
Institutions
- Union Hospital (HK)
- Ritsumeikan University (JP)
- Central South University (CN)
- University of Tsukuba (JP)
- Tsukuba University of Technology (JP)
- University of Tsukuba Hospital (JP)
- Wuhan Union Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Cachexia Sarcopenia and Muscle
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/jcsm.70161
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Hubei Province
- Chinese Pharmaceutical Association